Search

Displaying results 981 - 990 of 3917 in total
  1. Drug

    Etoposide

    go.drugbank.com/drugs/DB00773
    ApprovedInvestigational

    A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair b...

    Products: SINTOPOZID 100 MG/5 ML IV KON. INFUZYON COZELTISI ICEREN FLAKON, 1 ADET
  2. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Carbetocin

    go.drugbank.com/drugs/DB01282
    ApprovedInvestigational

    Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.

  4. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  5. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547].

  6. Drug

    Bovine type I collagen

    go.drugbank.com/drugs/DB10771
    ApprovedInvestigational

    Bovine collagen alpha-1 is a naturally occurring extracellular matrix protein which is found in tendons and other connective tissues. It plays a vital role in cell growth, differentiation, attachment, and migration . Often combined with ...

  7. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    In addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability.

  8. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  9. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    The authors concluded that oseltamivir use in healthy adults had small, non-specific effects on symptoms (where the time to first alleviation of symptoms was only reduced from 7 to 6.3 days), it had no … effect on hospitalizations, and that there was no evidence for any reductions in complications of influenza such as pneumonia.

  10. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.